Tretten Or Novothirteen Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tretten or novothirteen market research report is one of a series of new reports that provides tretten or novothirteen market statistics, including the tretten or novothirteen industry global market size, regional shares, competitors with the tretten or novothirteen market share, detailed tretten or novothirteen market segments, market trends, and opportunities, and any further data you may need to thrive in the tretten or novothirteen industry. This tretten or novothirteen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to shift towards prophylactic treatment regimens, development of extended half-life therapies, shift from plasma-derived therapies, focus on personalized medicine, and expansion of healthcare access. Major trends in the forecast period include advancements in recombinant technology, advancements in drug development, advancements in biotechnology, technological advancements in clotting factor replacement, and advancements in clinical research.

The increasing awareness of rare bleeding disorders is expected to boost the growth of the tretten or novothirteen market. Rare bleeding disorders, such as hemophilia, von Willebrand disease, and factor XIII deficiency, are conditions that hinder the blood’s ability to clot properly. The growing awareness of these disorders is driven by advancements in diagnostic technologies, patient advocacy, and educational campaigns, which contribute to earlier detection, improved treatment access, and better patient outcomes. Tretten (NovoThirteen) is used in treating rare bleeding disorders by providing a recombinant form of activated Factor XIII, which is crucial for stabilizing blood clots and reducing the risk of bleeding in patients with Factor XIII deficiency. For example, according to the National Institute for Health and Care Excellence, in 2022-2023, 2,069 people in the UK were diagnosed with hemophilia B, including 374 with severe cases and 351 with moderate cases. This increased awareness is contributing to the growth of the tretten or novothirteen market.

The rise in healthcare expenditure is also expected to drive the growth of the tretten or novothirteen market. Healthcare expenditure represents the total financial resources allocated to healthcare services by governments, businesses, and individuals, including medical treatments, hospital care, medications, and public health initiatives. The increase in spending is due to factors such as advancements in medical technology, a growing demand for healthcare services, and a heightened focus on quality patient care, which has led to more global investments. With increased healthcare expenditure, more funds are directed toward research, development, and the accessibility of treatments for rare and complex conditions such as congenital Factor XIII deficiency, which tretten is designed to treat. For instance, the Centers for Medicare and Medicaid Services reported that US healthcare spending rose by 4.1% in 2022, reaching a total of $4.5 trillion, surpassing the 3.2% increase from 2021. This growing expenditure is fueling the growth of the tretten or novothirteen market.

The rising demand for personalized medicine is another factor expected to propel the growth of the tretten or novothirteen market. Personalized medicine is a healthcare approach that tailors treatment plans to individual patients based on their genetic makeup, lifestyle, and environmental factors, aiming to enhance the effectiveness of care. The growing demand for personalized medicine is driven by advancements in genomics and diagnostic technologies, which enable more individualized and effective treatments. Tretten (NovoThirteen) serves as a form of personalized medicine by offering targeted treatment for patients with hemophilia B, addressing their specific clotting factor deficiencies and improving bleeding control while reducing the risk of bleeding episodes. For example, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from the six approvals in 2022. Among these new treatments, seven were cancer drugs, and three targeted other conditions. The rising demand for personalized medicine is thus contributing to the growth of the tretten or novothirteen market.

The key company operating in the tretten or novothirteen market is Novo Nordisk A/S.

North America was the largest region in the tretten or novothirteen market in 2024. The regions covered in tretten or novothirteen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tretten or novothirteen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tretten (Novothirteen) is a recombinant therapy designed to treat factor XIII deficiency, a rare bleeding disorder. It works by providing recombinant factor XIII, which helps stabilize blood clots by cross-linking fibrin strands. Typically administered through intravenous infusion, Tretten is also used in the treatment of conditions such as paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS) to reduce the risk of complications, such as organ damage or blood clot formation.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Tretten (Novothirteen) include hemophilia B and surgical prophylaxis. Hemophilia B is a genetic disorder caused by a deficiency of clotting factor IX, leading to impaired blood clotting and excessive bleeding. Tretten is available in various formulations, including lyophilized powder and intravenous solution. It is distributed through multiple channels, including hospitals, clinics, retail and specialty pharmacies, and is used by a range of patients, including both adults and children.

The tretten or novothirteen market consists of sales of plasma-derived factor XIII concentrates, diagnostic kits, assays, and ancillary products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.